

**Phase-I-Studien**  
**Studien offen für Accrual**  
**Klinik für Med. Onkologie und Hämatologie**  
**Kantonsspital St. Gallen**

EKSG / BASEC	Titel der Studie	PI	Bemerkungen	E-Mail PI
<b>All comer Studien</b>				
BASEC: 2016-00707	<p><b>SAKK 67/15 BASILEA / CDI-CS-003:</b>            An open-label Phase 1/2a study of BAL101553 administered as intravenous 48-hour infusions in adult patients with advanced solid tumors</p> <p><b>Expansion Kohorten offen:</b></p> <ul style="list-style-type: none"> <li>• Histologically-confirmed <b>ovarian, fallopian-tube or primary-peritoneal cancer</b> that is newly platinum-resistant or refractory</li> <li>• A histologically-confirmed <b>Glioblastoma</b> in first relapse.</li> </ul>	MJ	<b>Expansion offen, Slots vorhanden</b>	Markus.Joerger@kssg.ch
2017-00921	<p><b>MP0274</b>            A phase 1, first-in-human, single-arm, multi-center, open-label, repeated-dose, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors</p> <p><b>HER2-positive solid tumor malignancy. IHC3 can be enrolled, IHC2 need FISH to confirm positivity</b></p>	AO	<b>Slots auf Anfrage</b>	Aurelius.Omlin@kssg.ch Dagmar.Hess@kssg.ch
2017-01310	A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma	MJ	<b>Slots für IO-naiv: DLBCL</b> <b>Slots für IO-vorbehandelt: HNSCC, Melanoma</b>	Markus.Joerger@kssg.ch
2017-02227	An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas	MJ	<b>Slots für HER2- BC, Endometrium, Ovar</b> > Alle mit genetischen DNA Reparaturdefekten	Markus.Joerger@kssg.ch
2018-00641	<p><b>SAKK 65/16</b>            TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.</p>	DH	<b>All comers; slots auf Anfrage</b>	Dagmar.Hess@kssg.ch
2018-02302	A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers. (CA027-002)	MJ	<b>Studie bis auf weiteres „on hold“.</b>	Markus.Joerger@kssg.ch

**Phase-I-Studien**  
**Studien offen für Accrual**  
**Klinik für Med. Onkologie und Hämatologie**  
**Kantonsspital St. Gallen**

EKSG / BASEC	Titel der Studie	PI	Bemerkungen	E-Mail PI
<b>Haematological and Lymphoma</b>				
2015-00091	<p><b>EDO S101-1001</b>            Phase-I-study of EDO S101 ( alkylating histone deacetylase inhibition fusion molecule) in <b>relapsed/refractory hematologic malignancies</b></p> <p><b>Expansion cohort 1:</b> relapsed/refractory multiple myeloma  <b>Expansion cohort 2:</b> relapsed/refractory Hodgkin's lymphoma  <b>Expansion cohort 3:</b> relapsed/refractory peripheral T-cell lymphoma (PTCL)  <b>Expansion cohort 4:</b> relapsed/refractory cutaneous T-cell lymphoma (CTCL), subtypes mycosis fungoides (MF) and Sézary syndrome (SS)  <b>Expansion cohort 5:</b> relapsed/refractory T-cell Prolymphocytic leukemia (T-PLL)</p>	CD DH	<b>Slots auf Anfrage</b>	Christoph.Driessen@kssg.ch Dagmar.Hess@kssg.ch
<b>Lung Cancer</b>				
2016-01900	<p><b>SAKK 19/16:</b>            Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutations: A multicenter phase IB trial.</p>	MF	<b>Slots auf Anfrage</b>	Martin.Frueh@kssg.ch
<b>Melanoma</b>				
2019-01847 CTU17.0 22	<p><b>ENiGMA:</b>            Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of Tinostamustine (EDO-S101), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic MelAnoma</p>	MJ	<b>IO-naiv, erste oder zweite palliative Therapielinie</b>	markus.joerger@kssg.ch

Stand 15.05.2019 DH/AO/MJ/KK